exendin-4 glp 1 Exendin-4 - an overview |

Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions

One recent study found that people started gaining weight about eight weeks after stopping their medication

Seek urgent medical help if you experience severe persistent abdominal pain (with or without vomiting), signs of dehydration, or inability to keep fluids down, as these could indicate serious side effects

Many patients wonder whether they can inject GLP-1 medications above the belly button